Raymond E. Cabillot Sells 842 Shares of Pro-Dex, Inc. (NASDAQ:PDEX) Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 842 shares of the business’s stock in a transaction that occurred on Friday, March 28th. The shares were sold at an average price of $50.00, for a total value of $42,100.00. Following the transaction, the director now directly owns 278,945 shares in the company, valued at $13,947,250. This trade represents a 0.30 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Pro-Dex Stock Performance

Shares of PDEX opened at $55.19 on Thursday. Pro-Dex, Inc. has a one year low of $16.84 and a one year high of $59.60. The company has a 50-day simple moving average of $40.72 and a two-hundred day simple moving average of $40.53. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.58 and a quick ratio of 1.44. The firm has a market capitalization of $179.97 million, a PE ratio of 27.46 and a beta of 0.40.

Pro-Dex (NASDAQ:PDEX) last released its quarterly earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. On average, analysts anticipate that Pro-Dex, Inc. will post 2 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PDEX. OMERS ADMINISTRATION Corp purchased a new stake in Pro-Dex in the fourth quarter worth about $313,000. Millennium Management LLC purchased a new stake in shares of Pro-Dex in the 4th quarter worth approximately $260,000. 683 Capital Management LLC bought a new position in Pro-Dex during the 4th quarter valued at approximately $739,000. Northern Trust Corp raised its stake in Pro-Dex by 14.1% during the fourth quarter. Northern Trust Corp now owns 35,754 shares of the medical instruments supplier’s stock valued at $1,672,000 after buying an additional 4,426 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in Pro-Dex during the fourth quarter valued at $433,000. 15.28% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded shares of Pro-Dex from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.